Pharmstandard
Russian pharmaceutical company
From Wikipedia, the free encyclopedia
JSC Pharmstandard (Russian: ПАО "Фармстандарт", romanized: PAO "Farmstandart") is a Russian multinational[4] pharmaceutical company.[5] It is headquartered in Dolgoprudny, Moscow Oblast.
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | Dolgoprudny, Russia |
Area served | Worldwide |
Key people | Viktor Kharitonin (Chairman) Igor Krylov (CEO) |
| Products | Remedies |
| Revenue | $638 million[1] (2017) |
| $231 million[2] (2016) | |
| $119 million[2] (2016) | |
| Total assets | $1.41 billion[2] (2016) |
| Total equity | $936 million[2] (2016) |
Number of employees | 6,450[3] (2015) |
| Website | pharmstd.com |
Pharmstandard's makes and exports over 400 generic and proprietary drugs, including products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc.[citation needed]
The company has six manufacturing facilities located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk and Tyumen.
History
Pharmstandard was established in 2003 as a result of a merger.[5]
In May 2007 the company raised $880 million in an IPO, valuing the company at $2.2 billion.[6] Roman Abramovich owned a 17% stake in the company until March 2008.[7]
In 2013 the company announced plans to buy the ingredient supplier Bever Pharmaceutical, causing Pharmstandard shares to fall 25%.[8]
Pharmstandard was delisted from the London and Moscow stock exchanges in 2017.[9][10]